• Policy
• Policies at a standstill due to absence of MFDS minister
• by Lee, Jeong-Hwan Jun 15, 2022 05:50am

• Policy
• Lorviqua is about to be reimbursed
• by Lee, Tak-Sun Jun 15, 2022 05:50am

• Policy
• MFDS reviews EUA of COVID-19 prevention drug Evusheld
• by Lee, Hye-Kyung Jun 14, 2022 06:04am

• Policy
• Yoon Gov should increase bio-health investment by 15% per yr
• by Lee, Jeong-Hwan Jun 14, 2022 06:04am

• Policy
• A petition has been filed for public consent to Enhurtu
• by Lee, Jeong-Hwan Jun 13, 2022 05:55am

• Policy
• Novartis' new adult leukemia drug Scemblix has been approved
• by Lee, Hye-Kyung Jun 13, 2022 05:54am

• Policy
• The risk group for COVID-19 depression was 18.5%, down
• by Lee, Jeong-Hwan Jun 13, 2022 05:54am

• Policy
• Govt skeptical about using existing vaccines on monkeypox
• by Lee, Jeong-Hwan Jun 9, 2022 06:25am

• Policy
• Cases for Pre-approval of Ultomiris exceeds 100
• by Lee, Tak-Sun Jun 9, 2022 06:25am

• Policy
• Monkeypox becomes Class 2 infectious disease in Korea
• by Lee, Jeong-Hwan Jun 9, 2022 06:24am